KRYS News - Candlesense

Krystal Biotech to Present at Cantor Global Healthcare Conference 2025

(NASDAQ:KRYS) PITTSBURGH, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the Cantor Global Healthcare...

Conference

10 days ago

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

PITTSBURGH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB...

Will the updated development plan require additional financing, and what are the potential dilution or partnership implications for shareholders? How does the inhaled KB707 platform compare to existing IL‑2/IL‑12 immunotherapies and other NSCLC treatments in terms of efficacy, safety, and market potential? What is the anticipated timeline and regulatory pathway for the inhaled KB707 Phase 2/3 trials in NSCLC, and how might that affect near‑term valuation?

Clinical trials

22 days ago